Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03400826 · ClinicalTrials.gov registry record · Phase 2
Effects of Simvastatin on Uterine Leiomyoma Size
A Phase 2 study of Leiomyoma and Fibroid Uterus, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03400826: Recruiting Phase 2 study of Leiomyoma and Fibroid Uterus, sponsored by Johns Hopkins University.
NCT03400826 is a Phase 2 study of Leiomyoma and Fibroid Uterus that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 60 participants, below the 98-participant average among 8 other Leiomyoma trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03400826, a Phase 2 study of Leiomyoma and Fibroid Uterus, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to study the effect of simvastatin on the size of uterine fibroids.
Primary Outcome
Tumor size measured by ultrasound imaging comparing tumor volume using ultrasound imaging. The volume will be reported in Centimeter cubes. The largest radius of the tumor will be used to calculate the volume, this will be measured in centimeters.
Conditions Studied
Interventions
- DRUG Simvastatin 40mg
- DRUG Placebo 40 mg
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-08-20 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
What NCT03400826 shows while recruiting
NCT03400826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 98-participant average among 8 other Leiomyoma trials with a reported enrollment target (39% lower).
The record links to 5 conditions, with Leiomyoma appearing as the primary indexed condition, and to 2 interventions - of which Simvastatin 40mg is the first listed.
NCT03400826 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03400826 about?
NCT03400826 is a clinical study titled "Effects of Simvastatin on Uterine Leiomyoma Size". The study aims to study the effect of simvastatin on the size of uterine fibroids.
What is the current status of trial NCT03400826?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2018-08-20. Estimated completion is 2026-07-31.
What conditions does trial NCT03400826 study?
This clinical trial studies the following conditions: Leiomyoma, Fibroid Uterus, Leiomyoma, Uterine, Fibroid Tumor, Fibromyoma.
What interventions are being tested in trial NCT03400826?
The interventions under investigation include: Simvastatin 40mg (DRUG), Placebo 40 mg (DRUG).
Who is sponsoring clinical trial NCT03400826?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03400826 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03400826's enrollment target sits among peer trials
60 7th of 8 higher than 2 of 8 other Leiomyoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leiomyoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
COMPLETED · Phase 2
-
Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist
COMPLETED · Phase 2
-
An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms
RECRUITING · NA
-
Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)
RECRUITING
-
Prescription of Letrozole for Uterine Myoma
RECRUITING · Phase 4
-
Surgical Success After Laparoscopic vs Abdominal Hysterectomy
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI